Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods

Asthma causes enormous suffering and cost for children in the US and around the world [1 –3]. Co-morbid gastroesophageal reflux disease (GERD) makes asthma management more difficult due to increased symptoms. Proton pump inhibitor (PPI) drugs are effective at improving to GERD symptoms, however they have demonstrated only modest and variable effects on asthma control in the setting of co-morbid GERD. Importantly, PPI metabolism and efficacy depend on CYP2C19 genotype. The Genotype Tailored Treatment of Symptomatic Acid Reflux in Children with Uncontrolled Asthma (GenARA) study is a randomized, double-blind, placebo-controlled trial to determine if genotype-tailored PPI dosing im proves asthma symptoms among children with inadequately controlled asthma and GERD symptoms.

Source: Contemporary Clinical Trials - January 16, 2019 Category: Radiology Authors: Monica Tang, Kathryn V. Blake, John J. Lima, Edward B. Mougey, James Franciosi, Stephan Schmidt, Md Jobayer Hossain, Marjan Cobbaert, Bernard M. Fischer, Jason E. Lang Source Type: research